Verrica Doses First Patient in Second Pivotal Phase 3 Trial for YCANTH, Targeting Multi-Billion Dollar Wart Market
VRCA sits 72% above its 52-week low of $3.28 on light trading volume (0.3× avg).
Summary
Verrica Pharmaceuticals announced the dosing of the first U.S. patient in COVE-3, its second pivotal Phase 3 clinical trial for YCANTH (VP-102) for common warts. This follows the initiation of the first pivotal trial (COVE-2) in January and comes after the company issued a going concern warning in its Q1 2026 10-Q filing on May 12th. Advancing this late-stage clinical program is critical for Verrica, particularly given its limited cash runway. The company highlights a potential multibillion-dollar market opportunity for common warts, with no currently approved FDA therapies, making successful development a significant future revenue driver.
At the time of this announcement, VRCA was trading at $5.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.7M. The 52-week trading range was $3.28 to $9.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.